Rapeseed oleosomes facilitate intestinal lymphatic delivery and oral bioavailability of cannabidiol
Résumé
Due to high lipophilicity and extensive first-pass metabolic loss, cannabidiol (CBD) has low oral bioavailability. Co-administration of CBD and long-chain lipids facilitates the intestinal lymphatic delivery, resulting in higher systemic bioavailability, as well as high levels of the drug within the intestinal lymphatic system. However, despite previous attempts with various lipid-based formulations, the oral bioavailability of CBD is still limited. In this work, we have developed a novel formulation of CBD based on natural rapeseed oleosomes. In vivo studies in rats demonstrated that oral administration of CBD-loaded rapeseed oleosomes leads to substantially higher oral bioavailability and intestinal lymphatic targeting of CBD in comparison with rapeseed oil or artificial emulsion made of rapeseed oil and lecithin.
In vitro mechanistic assessments, including in vitro lipolysis and peroxide value determination suggest that the lower oxidative state of the oil in oleosomes in comparison to crude oil or artificial emulsion is likely to be the main factor responsible for the superior performance of the CBD-loaded rapeseed oleosomes in vivo. Although further investigation will be needed, the data suggest that natural seeds-derived oleosomes can be used as a promising lipid-based drug delivery platform promoting the bioavailability and lymphatic delivery of lipophilic drugs.
Mots clés
Cannabidiol Intestinal lymphatic delivery Lipid-based formulation Rapeseed oleosomes Oral bioavailability AUC
Area Under Curve BCS
Biopharmaceutical Classification System BSU
Bio-Support Unit CBD
Cannabidiol DDT
Dichlorodiphenyltrichloroethane HPLC
High-Performance Liquid Chromatography MLN
Mesenteric Lymph Nodes PC
Phosphatidylcholine PDA
Photodiode Array Ultraviolet SD
Standard Deviation SDS
Sodium Dodecyl sulphate TG
Triglycerides CYP
Cytochrome P450
Area Under Curve
BCS
Biopharmaceutical Classification System
BSU
Bio-Support Unit
CBD
Cannabidiol
DDT
Dichlorodiphenyltrichloroethane
HPLC
High-Performance Liquid Chromatography
MLN
Mesenteric Lymph Nodes
PC
Phosphatidylcholine
PDA
Photodiode Array Ultraviolet
SD
Standard Deviation
SDS
Sodium Dodecyl sulphate
TG
Triglycerides
CYP
Fichier principal
Ji-International Journal of Pharmaceutics-2025-668-124947.pdf (661.18 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|
